Ozempic Copy Claim in South Africa: Inside the Case Exposing a Regulatory Loophole

The lawsuit heard in the South African High Court reveals the copying of popular weight-loss injections and the severe challenges within regulatory authorities. The company Novo Nordisk filed a lawsuit against the firm iDexis, also known as Sentra Pharmacy, due to the unauthorized production and sale of products containing the active ingredient semaglutide. The court decided to temporarily halt the production, supply, and marketing of these products until an in-depth review of the process is completed. This incident is not only about the excessive profit greed of a single pharmacy; it also points to the problem of failing to properly oversee a rapidly growing medical market that outstrips the limits of regulations. Thus, the legal and ethical boundaries of peptide-based obesity and diabetes medications, which have gained global popularity, have begun to be debated in the public eye.

The production volume of the pharmacy in question has reached incredible proportions, according to information in the court files. Allegedly, iDexis reached a massive commercial volume by producing approximately 84,500 units of prescription-free and copy semaglutide per month. According to the company's own admission, this production amount is even higher than the total monthly sales of the original Ozempic and the competitor drug Mounjaro in the South African market. The monthly value of this massive operation is estimated to be around 50 million Rand (approximately 2.7 million US Dollars). Documents from the court process clearly show that this counterfeit drug production involved the abuse of exceptions granted in the law for individual personalized prescriptions, turning it into a massive commercial business model.

The South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC) made harsh interventions to protect public health. SAHPRA decided to issue a mandatory recall of peptide-based products such as synthetic semaglutide and tirzepatide belonging to the pharmacy in question, classifying them under the highest risk category, 'Class I, Type A'. It was determined that after this decision, which risked the health of consumers using the drugs, the pharmacy did not publish a proper withdrawal notice, but instead simply marked the products as 'out of stock'. Regulatory authorities intervened in the incident due to the non-compliance of the pharmacists and business officials directly involved, demonstrating the power of state authority. This crisis has starkly revealed how dangerous the spread of unregulated biological drugs can be and the consequences of a lack of oversight.

The scale of this medical scandal has not been limited to the manufacturing pharmacy alone, but has also opened the door to a broad investigation encompassing the doctors prescribing these drugs. The Health Professions Council of South Africa (HPCSA), involved in the incident for the first time, also clearly stated its stance with a joint statement issued alongside other regulatory authorities. The board announced that any professional who continues to use or stock these recalled drugs would be considered to have committed a disciplinary offense. Experts warned that healthcare workers who ignore this warning and prescribe them again will be prosecuted as individuals who knowingly 'endanger public health'. These steps could mark the beginning of a new security era that severely punishes not only the sellers but also the demand side of the illegal and unregulated counterfeit drug trade.

The legal and court processes have also revealed how slow the judicial system is in coping with modern medical crises. Even though the company Novo Nordisk made its first emergency application in this case in December 2024 to protect its patent rights and patient safety, the court decision was delayed until June 2026 due to procedural obstacles raised by iDexis. During this two-year delay, unregulated drug trade continued unabated and products were introduced to the market. It has been proven once again that regulatory systems in developing countries struggle to keep up with innovations and abuses in the rapidly growing 'peptide' and especially 'weight-loss drug' market. This new and unregulated market, formed by cheap synthetic raw materials originating from Asia following the expiration of global drug patents, will necessitate stricter global health measures worldwide in the future.